Recombinant Macaca fascicularis Angiotensin-converting enzyme (ACE2), partial (Active)

ACE2 serves as the primary receptor for SARS-CoV-2 spike protein entry, making this cynomolgus monkey ortholog a critical tool for translational studies bridging preclinical primate models and human infection biology. This recombinant construct spans residues aa 18–741, expressed in mammalian cells with a C-terminal hFc1 tag positioned to preserve the catalytic domain, and its binding activity has been validated by functional ELISA demonstrating an EC50 of 5.638–9.496 ng/ml against immobilized SARS-CoV-2 S1-RBD, confirming robust receptor–ligand interaction suitable for inhibitor screening, IC50 determination, and drug candidate evaluation studies. The confirmed binding competence also supports use as a positive control in enzyme-linked assays, while the protein provides a suitable basis for substrate specificity profiling and kinetic parameter analysis (Km, Vmax, kcat). Purity exceeding 90% by SDS-PAGE combined with endotoxin levels below 1.0 EU/μg meets the quality thresholds commonly required for accurate kinetic measurements and cell-based functional assays.